Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

Abstract Background Febuxostat immediate release (IR), a xanthine oxidase inhibitor, is indicated for the management of hyperuricemia in patients with gout by lowering urate levels. An extended release (XR) formulation of febuxostat was developed to provide equal or superior efficacy on urate loweri...

Full description

Bibliographic Details
Main Authors: Lhanoo Gunawardhana, Michael A. Becker, Andrew Whelton, Barbara Hunt, Majin Castillo, Kenneth Saag
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Arthritis Research & Therapy
Subjects:
Hyperuricemia
Renal impairment
Febuxostat
Extended release
Serum uric acid
Online Access:http://link.springer.com/article/10.1186/s13075-018-1593-0

Internet

http://link.springer.com/article/10.1186/s13075-018-1593-0

Similar Items